World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment

被引:25
作者
Champeaux, C. [1 ,2 ]
Jecko, V. [2 ]
机构
[1] Hop St Anne, Serv Neurochirurg, 1 Rue Cabanis, F-75014 Paris, France
[2] Hop Pellegrin, Serv Neurochirurg, F-33000 Bordeaux, France
关键词
WHO grade III meningioma; Malignant meningioma; Radiotherapy; Outcome; Prognostic factors; MALIGNANT MENINGIOMAS; RADIOTHERAPY; SURVIVAL; AKT1;
D O I
10.1016/j.neuchi.2016.05.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background. - To depict the outcome of patients with WHO grade III meningioma and identify factors that may influence the survival. Material and methods. - Between 1989 and 2007, a retrospective search identified 43 WHO grade III meningiomas after cases exclusion. Nine patients (39.5%) had a previous history of grade I or II meningioma. The patients underwent a total of 89 surgical resections and 83.7% received radiotherapy. Median follow-up was 7.4 years. Results. - At the end of the study, 35 patients were deceased (81.4%). One patient died of disseminated metastatic disease of a papillary meningioma. Median overall survival was 4.1 years, 95% CI [1.9, 8.3]. Overall survival probability at 1, 5 and 10 years were respectively: 81.4%, 95% CI [70.6, 93.9], 48.8%, 95% CI [36,66.3] and, 27.5%, 95% CI [16.9, 44.9]. In univariate Cox regression, a previous surgery for WHO grade I or II meningioma (HR=2.05, 95% CI [1.03, 4.07], P=0.04) and the mitosis count (HR=0.3, 95% CI [0.12, 0.79], P=0.02) were associated with the overall survival. However, neither macroscopic gross total resection (HR=0.87, 95% CI [0.4, 1.87], P=0.71), nor radiotherapy (HR=0.75, 95% CI [0.31, 1.83], P=0.53) was associated with an increased survival. Conclusion. - This series highlights the poor prognosis associate with the diagnosis of malignant meningioma. Patients with primary WHO grade III meningioma demonstrating less than 14 mitosis per 10 high power fields may live longer. We could not confirm the usefulness of complete resection and adjuvant radiotherapy. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 29 条
  • [21] LONG-TERM EXPERIENCE WITH WORLD HEALTH ORGANIZATION GRADE III (MALIGNANT) MENINGIOMAS AT A SINGLE INSTITUTION
    Rosenberg, Lewis A.
    Prayson, Richard A.
    Lee, Joung
    Reddy, Chandana
    Chao, Samuel T.
    Barnett, Gene H.
    Vogelbaum, Michael A.
    Suh, John H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (02): : 427 - 432
  • [22] RStudio Team, 2016, RStudio: integrated development for R
  • [24] Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas Clinical article
    Sughrue, Michael E.
    Sanai, Nader
    Shangari, Gopal
    Parsa, Andrew T.
    Berger, Mitchel S.
    McDermott, Michael W.
    [J]. JOURNAL OF NEUROSURGERY, 2010, 113 (02) : 202 - 209
  • [25] Therneau T., 2015, A package for survival analysis in R. R package version 3.2-7
  • [26] Therneau TM, 2000, STAT BIOL HEALTH
  • [27] Tournat Helene, 2006, Cancer Radiother, V10, P590, DOI 10.1016/j.canrad.2006.06.008
  • [28] Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas
    Yew, Andrew
    Trang, Andy
    Nagasawa, Daniel T.
    Spasic, Marko
    Choy, Winward
    Garcia, Heather M.
    Yang, Isaac
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (01) : 17 - 22
  • [29] Prognostic factors for patients with atypical or malignant meningiomas treated at a single center
    Zhao, Peng
    Hu, Mengqing
    Zhao, Meng
    Ren, Xiaohui
    Jiang, Zhongli
    [J]. NEUROSURGICAL REVIEW, 2015, 38 (01) : 101 - 107